Skip to main content

Table 3 Summary of studies in complicated urinary tract infection (cUTI)

From: Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options

  

CCR-TOC/ITTa

    

Index

Reference

Agent A

Agent B

Description

Quality

Comparative outcome (A vs B)

Year

M

[38]

Doripenem 95.1 % (272/286)

Levofloxacin 90.2 % (240/266)

P3, R

H

Noninferior

2009

N

[39]

Doripenem 94.1 % (511/543)

Levofloxacin 90.2 % (240/266)

See comments

H

Noninferior

2010

O

[40]

Ceftolozane-tazobactam 95.9 % (327/341) ME

Levofloxacin 93.2 % (329/353) ME

R, DB, P3

H

Noninferior

 

P

[41]

Ceftazidime-avibactam 85.7 % (24/28)

Imipenem-cilastatin 80.6 % (29/36)

P2, DB, R

M

-

2012

  1. CCR-TOC/ITT clinical cure rate at the test-of-cure endpoint intent-to-treat, DB double-blind, ME microbiological eradication, OL open-label, P2 phase 2, P3 phase 3, R randomized.
  2. aUnless otherwise noted.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us